Injection

Semaglutide Injection

Semaglutide

Long-acting GLP-1 receptor agonist with a 168-hour half-life enabling once-weekly subcutaneous dosing for type 2 diabetes (Ozempic, up to 2mg) and chronic weight management (Wegovy, 2.4mg), with proven cardiovascular risk reduction in the SUSTAIN and STEP trial programs. Available as a pre-filled pen from Novo Nordisk-aligned and Indian generic manufacturers and exported globally as one of the most prescribed GLP-1 agents for diabetes and obesity.

Strengths

0.25mg / 0.5mg / 1mg / 2.4mg

Packing

1 pre-filled pen/box

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request Quotation WhatsApp

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition

Semaglutide 0.25mg / 0.5mg / 1mg (Ozempic) or 2.4mg (Wegovy) per dose

Dosage Form

Injection

Available Strengths

0.25mg / 0.5mg / 1mg / 2.4mg

Packing

1 pre-filled pen/box

Route of Administration

Subcutaneous injection, once weekly

Dosage

Diabetes: start 0.25mg weekly, escalate to 0.5mg then 1mg; Weight: escalate to 2.4mg weekly

Indications

Type 2 diabetes, chronic weight management (2.4mg dose), cardiovascular risk reduction

Country of Origin

India (WHO-GMP Certified)

Storage

Store at 2-8°C; in-use pen at room temperature up to 30°C for 56 days

Shelf Life

24 months

Side Effects

Nausea, vomiting, diarrhea, abdominal pain, constipation, headache

Precautions

Thyroid C-cell tumor risk; pancreatitis monitoring; hypoglycemia with sulfonylureas/insulin; gallbladder disease; avoid in pregnancy

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Injection

Retatrutide Injection

Retatrutide

Investigational triple incretin receptor agonist (GIP/GLP-1/Glucagon) demonstrating exceptional weight loss exceeding 24% body weight in Phase 2 trials, surpassing all currently approved anti-obesity medications and representing the next generation of metabolic therapies. Supplied by Indian manufacturers for research procurement and supplied to markets where investigational compounds are accessible under physician oversight.

5mg / 10mg / 20mg

Injection

Tirzepatide Injection

Tirzepatide

First-in-class dual GIP/GLP-1 receptor agonist (twincretin) demonstrating superior HbA1c reduction and up to 22.5% body weight loss in SURPASS and SURMOUNT trials, outperforming semaglutide across all dose levels in head-to-head studies. Available in six escalating weekly dose strengths as a single-dose auto-injector pen, supplied by Eli Lilly-aligned and Indian generic manufacturers for diabetes and obesity management globally.

2.5mg / 5mg / 7.5mg / 10mg / 12.5mg / 15mg

Tablet

Semaglutide Tablets

Semaglutide

World's first oral GLP-1 receptor agonist (Rybelsus) utilizing SNAC absorption technology to enable gastrointestinal uptake of this large peptide molecule, providing once-daily tablet convenience for type 2 diabetes management with HbA1c reductions comparable to injectable GLP-1 agonists. Supplied in 30-tablet bottles from Novo Nordisk-aligned and Indian manufacturers and exported for diabetes management programs preferring non-injectable therapy.

3mg / 7mg / 14mg

Need bulk pricing for Semaglutide Injection?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote